In viral hepatitis B and HCC, the cGAS-STING signaling pathway plays an inhibitory role during disease progression, while in ALD and NAFLD, it plays a promoting role. This evidence concerns the gene STING1 and metabolic dysfunction-associated steatotic liver disease.